INTRODUCTION {#sec1-1}
============

Hepatocellular carcinoma was the second most common cancer death in males and 7^th^ amongst females in 2012 worldwide.[@ref1]-[@ref3] In Pakistan frequency of hepatobiliary malignancy in males is 10.7% of all cancers.[@ref4] Prevalence of HCC in Pakistan varies 3.5-16% of all malignancies and Chronic Hepatitis B, C and D related cirrhosis are major causes. In two different studies frequency of HCC in Pakistan secondary to HCV is 87%, 66% and in HBV 22% and 43% has been reported.[@ref5] This deadly complication can be prevented by putting the patients at risk in regular surveillance programme.[@ref6] According to American association for the study of liver disease (AASLD) guidelines any mass in Chronic Liver Disease (CLD) patients is likely HCC.[@ref7] AASLD and European Association for the study of liver (EASL) disease recommends six monthly Ultrasound liver and serum AFP to avoid missing fresh cases.[@ref8] In this era of high public awareness and social media still our patients are ignorant about the serious consequences of hepatitis. Historically patients present late despite being symptomatic and impairment of liver functions. According to a report, majority of patients presents when very limited treatment options of cure and less than 1% chances of resection left.[@ref8] Less than 10% HCC patients are diagnosed with screening in Pakistan.[@ref9],[@ref10] This fact has been pointed out in a number of studies but there are very few studies that exactly quantify this issue, that's why this study was done to identify the stage at presentation of HCC in our population in order to increase awareness among health professionals to be vigilant to identify HCC earlier so that curative options of treatment can be exercised.

METHODS {#sec1-2}
=======

This cross sectional was carried out at CMH Multan from August 2017 to April 2018 with ethical approval by ethical committee of the Hospital. (August 21, 2019) A total of 135 patients with diagnosis of Hepatocellular Carcinoma were included using nonprobability convenience sampling technique after informed consent from the patients.

Study population comprised of patients presenting in CMH Multan, a tertiary care hospital, for follow up of DCLD, had SOL (space occupying lesion) confirmed HCC after investigations mentioned below were included. Patients having SOL liver other than HCC, with incomplete records and on treatment, not alive or unwilling to be part of study were excluded.

Demographic data including age, and gender were noted. Basic investigation including complete blood counts, liver functions including serum albumin, INR and renal function tests were done. Serology for Hepatitis B, C and D was done. Autoimmune profile including antinuclear antibody (ANA), anti-smooth muscle, anti-liver kidney and anti-mitochondrial antibodies were done to find out etiology. Serum ferritin, cerulo-plasmin, 24 urinary copper levels wherever required were carried out to rule out hemochromatosis and Wilson's disease. Abdominal ultrasound was performed. Space occupying lesions in the background of chronic liver disease were further investigated for HCC that included serum α fetoprotein and Tri-phasic CECT abdomen.

After establishing the diagnosis staging was done by BCLC and Melan's criteria.[@ref11] It is based on tumor size, its spread, patients' performance status assessed by ECOG criteria.[@ref12] Severity of the underlying chronic liver disease was assessed by Child Pugh[@ref13],[@ref14] and MELD[@ref15] criteria.

Patients with Child Pugh score of 5-6 were classified as Child Class A, those with 7-9 were classified as Child Class B while those with Child Pugh score of 10-15 were classified as Child Class C. MELD score was calculated according to following formula:

MELD = 3.8\[Ln serum bilirubin (mg/dL)\] + 11.2\[Ln INR\] + 9.6\[Ln serum creatinine (mg/dL)\] +6.4, where Ln is the natural logarithm

Data was entered in SPSS v 22.0. Frequencies of patients according to gender, hepatitis status, treatment status, time since diagnosis of hepatocellular carcinoma, child class, BCLC staging and ECOG performance status were determined. Descriptive statistics were applied. Means and Standard Deviations were determined for Age, Serum Total Bilirubin, Albumin, INR, Child Score, Serum Creatinine Levels, and Total Leukocyte Count, Hemoglobin levels (Hb), Platelet Count, Alpha Fetoprotein, ALT, ALK and MELD score.

RESULTS {#sec1-3}
=======

Patient characteristics like gender, status of hepatitis, previous history of hepatitis treatment, time since diagnosis of HCC, Child Class, BCLC Stage and ECOG Performance status of 135 included patients have been displayed in [Table-I](#T1){ref-type="table"}.

###### 

Profile of Patients included in present study.

  Gender                                                                    Frequency   Percentage
  ------------------------------------------------------------------------- ----------- ----------------------
  Male                                                                      106         78.5
  Female                                                                    29          21.5
  ***Hepatitis Status***                                                                
  Hepatitis C                                                               109         80.7
  Hepatitis B&C                                                             4           3.0
  Hepatitis B                                                               14          10.4
  Non B&C                                                                   4           3.0
  Cryptogenic                                                               4           3.0
  ***Anti-viral treatment for chronic hepatitis***                                      
  Received                                                                  37          27.4
  Not received                                                              98          72.6
  Time since diagnosis of HCC                                               85          63.0
  \<1 month                                                                 18          13.3
  1-3 months                                                                13          9.6
  3-6 months                                                                6           4.4
  6-12 months                                                               7           5.2
  12-18 months                                                              1           0.7
  2-2.5 years                                                               3           2.2
  \>2.5 years                                                               2           1.5
  ***Child Class***                                                                     
  A                                                                         49          36.3
  B                                                                         63          46.7
  C                                                                         23          17.0
  ***BCLC Stage***                                                                      
  Stage 0                                                                   4           3.0
  Stage A                                                                   16          11.9
  Stage B                                                                   78          57.8
  Stage C                                                                   34          25.2
  Stage D                                                                   3           2.2
  ***ECOG Performance Status***                                                         
  Fully active                                                              21          15.6
  Restricted physical activity, able to do sedentary work                   55          40.7
  Ambulatory capable of self-care unable to carry out any work activities   30          22.2
  Self-limited care on chair more than 50% working hours                    26          19.3
  Completely disable cannot carry on any self-care                          3           2.2
                                                                                        
  *Parameters*                                                              *Mean*      *Standard Deviation*
                                                                                        
  Age of the patient                                                        59.05       9.02
  Bilirubin (umol/L)                                                        1.47        0.74
  Albumin (g/L)                                                             1.93        0.68
  INR                                                                       1.47        1.40
  Child Score                                                               7.37        2.13
  Serum Creatinine umol/l                                                   99.70       70.67
  TLC                                                                       7.53        3.16
  Hb of the patient g/dl                                                    10.71       2.33
  Platelet count                                                            159.54      93.95
  Alpha Fetoprotein                                                         2169.14     7914.81
  ALT                                                                       79.62       61.41
  ALK                                                                       318.37      163.25
  MELD Score                                                                12.48       5.92

Patient Characteristics as per BCLC Staging have been shown in [Table-II](#T2){ref-type="table"} and [III](#T3){ref-type="table"}. It was observed that most of patients belonged to stage B irrespective of Gender, Status of Hepatitis, treatment Status, duration since diagnosis and ECOG performance status. 103 (85%) of the patients were diagnosed to have HCC recently or on index admission.

###### 

Patient Characteristics as per BCLC Staging.

                                                                            BCLC staging                                
  ------------------------------------------------------------------------- ------------------------ --- ---- ---- ---- ---
  Sex of the patient                                                        Male                     4   14   56   29   3
  Female                                                                    0                        2   22   5    0    
  Hepatitis status                                                          Hepatitis C              4   14   64   25   2
  Hepatitis B&C                                                             0                        0   1    3    0    
  Hepatitis B                                                               0                        1   8    4    1    
  Non B&C                                                                   0                        0   2    2    0    
  Cryptogenic                                                               0                        1   3    0    0    
  Treatment for the disease before                                          Yes                      1   11   15   9    1
  No                                                                        3                        5   63   25   2    
  Diagnosis HCC since                                                       Diagnosis on admission   4   10   45   24   2
  \<1 month                                                                 0                        3   13   2    0    
  1-3 months                                                                0                        1   7    4    1    
  3-6 months                                                                0                        1   4    1    0    
  6-12 months                                                               0                        0   6    1    0    
  12-18 months                                                              0                        0   1    0    0    
  18-24                                                                     0                        0   0    0    0    
  2-2.5 years                                                               0                        0   2    1    0    
  \>2.5 years                                                               0                        1   0    1    0    
  ECOG Performance status                                                   Fully active             2   4    11   4    0
  Restricted physical activity, able to do sedentary work                   0                        6   38   11   0    
  Ambulatory capable of self-care unable to carry out any work activities   0                        4   17   9    0    
  self-limited care on chair more than 50% working hours                    2                        2   12   9    1    
  completely disable cannot carry on any self-care                          0                        0   0    1    2    
  Dead                                                                      0                        0   0    0    0    

###### 

Patient Profile as per BCLC staging.

                     BCLC staging                                
  ------------------ -------------- -------- --------- --------- --------
  TLC                7.68           6.28     7.60      7.66      10.87
  Hb                 11.00          10.41    10.69     11.21     6.87
  Platelet count     182.00         107.19   165.40    169.21    147.33
  Serum Creatinine   99.27          82.42    100.98    97.01     189.67
  ALT                74.50          60.94    86.18     72.50     96.67
  ALK                362.00         262.69   318.38    343.71    269.67
  Billirubin         1.25           1.44     1.38      1.59      3.00
  Albumin            1.50           2.13     1.87      2.03      2.00
  INR                1.00           2.44     1.34      1.32      2.33
  child score        5.75           7.31     7.14      7.76      11.67
  AFP                324.85         68.01    2028.21   3877.34   139.30

Above table points 98(72%) HCC patients never got any sort of antiviral therapy before that indicates a big gap between general population and health providers.

DISCUSSION {#sec1-4}
==========

Incidence of HCC is more in men especially in HCV prevalent areas of United States,[@ref16] same is the case in our study i.e. majority are males with HCV between ages of 55 to 64 years. Age-specific rates of men in high-risk African populations (e.g. Gambia and Mali) peak in the 60 to 65 age group and women peak between 65 and 70 years old. These variations of age-specific patterns are most likely related to the differences in the dominant hepatitis virus in the population, the age at viral infection as well as the existence of other risk factors. In India Hepatitis B followed by C was most common cause of HCC.[@ref17] For the better patient's survival and to detect new HCC cases early, surveillance of patients with chronic Liver disease has been over emphasized in a number of studies and guidelines[@ref7],[@ref18]-[@ref20], but unfortunately 73.8% of our patients were totally unaware about their hepatitis status, didn't get any specific treatment before and 64% came to know about HCC on the index admission for the first time. This indicates a big gap in communication between health care providers and the patients. Prognosis and treatment plan is assessed by most widely accepted BCLC staging system. According to it in stage A, hepatic resection, liver transplantation is possible, in stage B patients are asymptomatic and have multinodular tumor and in Stage C along with previous features, patient has vessel invasion or extrahepatic spread. Only palliative treatment is possible at Stage B & C.[@ref10],[@ref21] Situation is better in India where about half of the patients had BCLC stage A and B in whom definitive therapy could be offered and 65% (688/1062) of HCC were due to HBV and HCV.[@ref22] One hundred and twenty-one (83.44%) our patients were in BCLC stage B&C with performance status (ECOG) one and above and average Child score seven, when nothing can be done much except palliative treatment. This advanced stage diagnosis is quite high as compared to average global HCC presentation at palliation stage is 25-75%.[@ref23],[@ref24] The most common BCLC stage at diagnosis was stage C in North America, Europe, South Korea and China, and stage A in Japan and Taiwan. In Japan and Taiwan, approximately 70% of patients were diagnosed with HCC at BCLC stage 0 or A, and less than 20% were diagnosed at BCLC stage C or D.[@ref25] Above studies points better surveillance programme in Japan and Taiwan than North America and Europe. Further its need to stress more on implementation of the guidelines rather making more strict surveillance programs. Out of the two scoring models currently being used to assess the severity and prognosis of CLD patients i.e. CTP and MELD.[@ref12]-[@ref14] MELD is preferred over CTP because of the subjectivity in the later. MELD has been adapted by United Network Organ sharing (UNOS) to prioritize the Cadaveric organ donation of Liver. MELD now is also in consideration to be adopted in different world areas and countries. MELD score assigned specific score in HCC patients depending upon the tumor burden and three months survival renders more proportion of organ donations in this group.[@ref26] Reason for assigning additional scores are, HCC patients may not demonstrate the degree of hepatic synthetic dysfunction necessary to give them a competitive MELD score, secondly in absence additional points may make them unfit for surgery after three months. In our study BCLC stage B, PS one and above, average CTP score of seven, class B, MELD 12 comes under the heading of more tumor burden and advanced disease and unfortunately don't merit the priority for transplantation. Only options left are trance arterial chemo embolization (TACE) or tyrosine kinase inhibitors drugs like Sorefenib.

CONCLUSION {#sec1-5}
==========

HCC is a sinister complication of Chronic Liver Disease but majority of our patients are diagnosed at advanced stage of the disease with high mortality and limited treatment options.
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